Abstract
Background: Etanercept, a fully human soluble receptor tumor necrosis factor (TNF) antagonist, is currently approved for the treatment of rheumatoid arthritis (RA), juvenile RA, and psoriatic arthritis and is being studied for the treatment of psoriasis. To help determine an optimal dosing regimen of etanercept in the psoriasis indication, the steady-state pharmacokinetics (PK) of etanercept was compared at different dose levels and schedules in patients with psoriasis or RA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
